Real-World Evidence (RWE) refers to clinical insights derived from the analysis of Real-World Data (RWD)—data generated in routine practice outside randomized controlled clinical trials. This includes electronic health records, health insurance data, patient registries, wearable data, and data from observational studies. RWE complements the efficacy evidence generated in controlled trials with effectiveness insights under real-world care conditions and is rapidly gaining importance in regulatory approval, Health Technology Assessment (HTA), and post-marketing surveillance.
Terminological and conceptual distinction between RWD and RWE
Real-World Data (RWD) is the raw material: unstructured or structured data collected in the context of medical care, in patient registries, or via digital devices. Real-World Evidence (RWE) is generated only through a methodologically sound analysis of these data with the aim of deriving clinically relevant insights. The quality of RWE depends directly on the quality of the data source, the completeness of documentation, and the suitability of the statistical methods. Missing data, selection bias, and confounding are the key methodological challenges in generating valid RWE.
Regulatory status and acceptance
In 2018, the FDA established a structured framework for the use of RWE in regulatory decision-making with the “Real-World Evidence Program”. In the EU, the EMA has published corresponding guidance on the use of RWD/RWE and advanced the European Health Data Space (EHDS) project, which aims to standardize cross-border data access within the EU. For label expansions (line extensions), rare diseases, or pediatric indications, authorities increasingly accept RWE as a supplementary or even primary source of evidence. However, for a regulatory submission, RWE studies must be prospectively planned, documented in a protocol, and registered to ensure transparency regarding bias risks.
For the registration and publication of RWE studies, the EMA’s EU PAS Register has become established. All PASS studies as well as many voluntary observational studies are documented there and are publicly accessible. Transparency and prospective registration are now indispensable for the regulatory and scientific acceptance of RWE studies and are regarded as a mandatory quality standard in modern RWE research, significantly increasing the credibility of study results with regulatory authorities, HTA bodies, and the scientific community.
Methods for generating RWE
A range of tools is available for methodologically robust analysis of RWD. Propensity score matching balances treatment and control groups based on observable confounders, thereby reducing selection bias. Instrumental variables help address unobserved confounding. Target trial emulation is a newer approach in which a hypothetical randomized trial is reconstructed from observational data—including eligibility criteria, intervention, follow-up, and endpoint. Sensitivity analyses assess the robustness of results to methodological assumptions. Every RWE study should be registered in advance (e.g., in ClinicalTrials.gov or the EU PAS Register) and accompanied by a transparent study protocol.
In addition to regulatory use, RWE is playing an increasing role in commercial decision-making in the pharmaceutical industry: portfolio decisions, dose finding for post-marketing studies, and the identification of high-risk groups are increasingly supported by RWD analyses. Digital health platforms and patient-reported outcomes (PROs) significantly expand the available data base. Methodological standards for PRO-based RWE are rising: authorities expect valid, reliable measurement instruments as well as a pre-registered analysis strategy.
RWE in Health Technology Assessment
HTA bodies such as IQWiG in Germany, NICE in the United Kingdom, or HAS in France are increasingly using RWE in the assessment of the added benefit of new medicines. Particularly in rare diseases, where randomized trials can include only limited patient numbers, RWE from registries and routine care data complements the evidence used for approval. With the EU HTA Regulation (EU) 2021/2282, which will apply from January 2025 for oncology products and ATMPs, RWE will play an important role in joint clinical assessments at EU level. Sponsors must prepare early for requirements regarding data transparency and methodological standards.
In clinical practice, platform trials and adaptive study designs that integrate RWE components are also gaining importance. So-called pragmatic clinical trials (PCTs) are conducted under routine care conditions and generate data that lie between classic RCT evidence and observational data. They offer authorities and HTA bodies an attractive bridge between efficacy and effectiveness. For sponsors, the growing importance of RWE primarily represents an organizational challenge: data governance structures, data protection concepts, and quality assurance for heterogeneous data sources must be integrated into study planning at an early stage.
Frequently Asked Questions
Can Real-World Evidence replace a randomized clinical trial?
In most regulatory approval scenarios, the randomized controlled trial (RCT) remains the gold standard for demonstrating causal effects. In certain contexts, RWE can complement an RCT or—particularly in rare diseases, pediatric indications, or specific extension scenarios—be recognized as a primary source of evidence. Regulatory acceptance depends strongly on study quality, methodological transparency, and the relevance of the research question.
Which specific data sources are best suited for modern RWE studies?
Suitable sources include electronic health records (EHRs), health insurance claims data, disease registries, biosample databases, mHealth data (wearables, apps), and data from non-interventional studies. The decisive factor is data quality: completeness, consistency, representativeness of the captured population, and a clear definition of the variables required for the research question.
What is the difference between efficacy and effectiveness?
Efficacy describes the effect of a medicinal product under controlled study conditions (an ideal setting with selected patients). Effectiveness describes the effect in real-world care with more heterogeneous patient populations, comorbidities, and variable conditions of use. RWE is the key instrument for generating effectiveness data, thereby closing the gap between clinical trials and actual patient benefit.